TY - CHAP
T1 - Clinician update: Direct thrombin inhibitors and low molecular weight heparins in acute coronary syndrome
AU - Wykrzykowska, Joanna J.
AU - Kathiresan, Sekar
AU - Jang, Ik-Kyung
PY - 2005/1/1
Y1 - 2005/1/1
N2 - Thrombin plays a central role in the pathogenesis of acute coronary syndromes (ACS) including both unstable angina (UA) and acute myocardial infarction (AMI) (1). It promotes platelet aggregation, its own autocatalysis, and catalysis of fibrinogen to fibrin (2,3). Antithrombin and antiplatelet therapies have become the cornerstones of the treatment of cardiovascular disease. The usual medical regimen for non-ST segment elevation MI includes intravenous unfractionated heparin (UFH), aspirin, thienopyridine, and glycoprotein IIb/IIIa inhibitors, and for ST-elevation MI, aspirin, UFH, and thrombolytic agents.
AB - Thrombin plays a central role in the pathogenesis of acute coronary syndromes (ACS) including both unstable angina (UA) and acute myocardial infarction (AMI) (1). It promotes platelet aggregation, its own autocatalysis, and catalysis of fibrinogen to fibrin (2,3). Antithrombin and antiplatelet therapies have become the cornerstones of the treatment of cardiovascular disease. The usual medical regimen for non-ST segment elevation MI includes intravenous unfractionated heparin (UFH), aspirin, thienopyridine, and glycoprotein IIb/IIIa inhibitors, and for ST-elevation MI, aspirin, UFH, and thrombolytic agents.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056955879&origin=inward
M3 - Chapter
SN - 0824754190
T3 - Clinical, Interventional and Investigational Thrombocardiology
SP - 495
EP - 524
BT - Clinical, Interventional and Investigational Thrombocardiology
PB - CRC Press
ER -